If you lead an MSL team today, you already know the feeling. Your team has access to more technology than ever — a CRM for engagement tracking, a KOL database for profiling, a compliance system for documentation, an analytics dashboard for reporting, and probably a spreadsheet or two holding the territory plans together. Each tool does something useful. None of them talk to each other. And your MSLs spend the first 90 minutes of every day toggling between systems, manually transferring data, and trying to assemble a coherent picture of their territory from five incomplete sources.
This is not a training problem. It is not a change management problem. It is a structural one. The MSL technology stack was not designed — it was accumulated. Each tool was built for a different buyer, optimized for a different workflow, and sold on a different value proposition. The result is a patchwork that creates more friction than it eliminates.
Understanding why requires looking honestly at what each layer of the stack does well, where it falls short, and why the gaps between tools matter more than the tools themselves.
The Current MSL Technology Stack
CRM and Engagement Tracking
Veeva CRM dominates Medical Affairs engagement tracking, and for good reason. It handles interaction logging, compliance workflows, and call planning with a level of regulatory awareness that general-purpose CRMs lack. IQVIA OCE has made inroads, particularly in organizations already invested in the IQVIA data ecosystem, and Salesforce Health Cloud serves teams that want to stay within the Salesforce platform.
What these platforms do well is undeniable: they create an auditable record of every interaction, enforce compliance guardrails, and provide a structured workflow for call planning. For commercial field teams — which is what they were originally built for — this is exactly right.
The problem is that MSL workflows are fundamentally different from sales rep workflows. A sales rep has a defined call cadence, a product message, and a measurable outcome (prescriptions). An MSL has a relationship-building mandate, non-promotional constraints, and outcomes that unfold over months or years. The CRM captures the interaction. It does not capture the relationship. It logs what happened on Tuesday. It cannot tell you whether your engagement strategy with a particular KOL is working, stalling, or heading in the wrong direction.
KOL Identification and Profiling
This is where the dedicated Medical Affairs tools live. IQVIA KOL Manager has been the incumbent for years, offering large-scale publication indexing, conference tracking, and tiered KOL classification. H1 (now part of Definitive Healthcare) brought a more modern interface and broader data sources to the category. Monocl carved a niche in expert network mapping with strong visualization capabilities. Veeva Link extended the Veeva ecosystem into KOL data, creating a tighter loop between profiling and engagement.
These tools provide genuine value. They aggregate publication histories, track conference appearances, map co-authorship networks, and create standardized profiles for thousands of HCPs. For identifying well-published academic KOLs in a defined therapeutic area, they work.
Where they break down is subtler. KOL databases are fundamentally retrospective — they tell you who was influential based on publications from 12 to 24 months ago. They update quarterly at best, annually in practice. They are optimized for the top 1-3% of HCPs by publication volume and conference presence. And they treat KOL profiling as a static deliverable — a report to be generated — rather than a continuously evolving intelligence layer. For teams trying to identify emerging voices, track shifting treatment paradigms, or find high-influence community-level treaters, these tools are structurally limited.
Territory and Engagement Planning
This is the least tooled part of the MSL workflow, which is remarkable given how central it is to MSL effectiveness. Territory planning — deciding which KOLs to prioritize, how to sequence engagements, what topics to lead with — is overwhelmingly done in spreadsheets. Sometimes it lives in a CRM module that was designed for sales territory management and repurposed for Medical Affairs. Occasionally, Aktana or a similar AI-driven tool provides next-best-action suggestions, though these are far more common on the commercial side.
The absence of dedicated MSL planning tools means that the most strategic part of an MSL's work — the part that determines whether their engagements create real scientific value — is the part with the least technological support. Territory plans are built once per quarter, rarely updated, and disconnected from the real-time data that should inform them.
Insights Management
After every meaningful interaction, MSLs capture insights — observations about treatment practices, unmet needs, competitive intelligence, and clinical concerns. Veeva Vault MedComms is the most common repository for these insights. Some organizations have built custom solutions on SharePoint or internal platforms. Others rely on CRM text fields.
The capture happens. What does not happen, in most organizations, is synthesis. Insights sit in individual records, tagged with a therapeutic area and perhaps a category code. Occasionally someone exports them to a slide deck for a quarterly review. But the systematic analysis — recognizing that eight different MSLs across four regions are hearing the same concern about a treatment gap, or that sentiment around a competitor product shifted three months before the data showed it — that almost never happens. The data is there. The intelligence is not.
Analytics and Reporting
The reporting layer is typically Tableau, Power BI, or a custom-built dashboard. These tools visualize data well. The problem is upstream: they are pulling from disconnected sources, each with its own data model, update cadence, and definition of basic entities. A KOL in the CRM may not map cleanly to the same KOL in the profiling tool. An insight logged in Vault cannot be correlated with engagement frequency in the CRM without manual effort. The dashboards look polished. The data underneath is fragmented.
The Five Structural Problems
The individual tools are not the issue. Many of them are well-built products that serve their specific function adequately. The issue is structural — it lives in the gaps between tools, in the assumptions baked into each platform, and in the accumulated architecture of a stack that was never designed as a stack.
Problem 1: Tools Built for Sales, Adapted for Medical
The foundational layer of most MSL technology stacks — the CRM — was designed around a sales workflow. Call planning, message delivery, sample tracking, prescription attribution. Veeva CRM is, at its core, a sales force automation platform with a Medical Affairs module bolted on. IQVIA OCE follows the same pattern. Salesforce Health Cloud is a horizontal platform stretched to fit.
This matters more than it appears. When the CRM is built for sales, the data model reflects sales assumptions. Interactions are atomic events, not chapters in an ongoing relationship. Success is measured by activity volume, not engagement depth. The system incentivizes logging, not learning.
MSL engagement is peer-to-peer. It unfolds over months. It is non-promotional. The value is in the relationship trajectory, not the individual touchpoint. Adapting a sales tool for this is like fitting a commercial cockpit into a research submarine — you can make the instruments display, but the controls do not match the environment.
The downstream effects are real. MSLs spend time on data entry that does not reflect their actual work. Managers get activity dashboards that do not capture actual impact. Strategic decisions are made on metrics designed for a different function.
Problem 2: Static KOL Data in a Dynamic World
KOL identification platforms operate on a publication-and-conference model that is inherently backward-looking. They index papers that were published months ago, track presentations from conferences that happened last quarter, and update their databases on a fixed schedule.
The research landscape does not operate on a quarterly cadence. A KOL who was peripheral six months ago may have just published a landmark Phase III trial result. A previously prominent voice may have shifted their research focus entirely. A community physician may be gaining influence through clinical practice and regional networks in ways that never appear in PubMed.
Static data produces static strategy. When your KOL tiering was built on data that is six months old, your territory plans are six months out of date before your MSLs make their first call. The organizations that consistently engage the right KOLs at the right time are doing it despite their tools, not because of them — usually through the institutional knowledge of experienced MSLs who know their territory through years of relationship building.
That knowledge is invaluable, but it does not scale. It leaves when the MSL leaves. And it cannot cover the breadth of a therapeutic landscape that is producing thousands of new publications, hundreds of new trial results, and continuous shifts in treatment guidelines every year.
Problem 3: The Integration Tax
Every MSL pays a daily tax for using a fragmented stack. It is not dramatic — it is the quiet accumulation of friction. Logging into the CRM to check the last interaction. Switching to the KOL database to review a publication profile. Opening a spreadsheet to check the territory plan. Going back to the CRM to log the new interaction. Copying key details into the insights system. Checking email for the latest competitive intelligence report.
Industry estimates put this integration tax at 30-40% of an MSL's productive time. For a team of 50 MSLs, that is the equivalent of 15-20 full-time employees spent on data wrangling rather than scientific engagement. The cost is not just in time — it is in the insights that are lost in the gaps, the connections that are never made, and the strategic opportunities that are invisible because the data lives in silos.
The standard response to this problem has been integration middleware — APIs, data warehouses, custom connectors. These help, but they are expensive, brittle, and they create a new dependency: someone has to maintain them. Every vendor update risks breaking the integration. Every new tool requires a new connector. The integration layer becomes its own project, with its own budget and its own headcount. This is the tax on top of the tax.
Problem 4: The Community Treater Blind Spot
Legacy KOL tools were built to surface academic thought leaders — the physicians who publish prolifically, present at major conferences, serve on advisory boards, and lead clinical trials. These are important people. They are also a tiny fraction of the physicians who treat patients.
The vast majority of patients in any therapeutic area are treated by community-based physicians who rarely publish, seldom present at national conferences, and never appear in traditional KOL databases. These treaters influence treatment decisions at scale. They are often the first to encounter real-world efficacy and safety signals. They shape formulary decisions at the local level. And they are, from the perspective of most MSL technology, invisible.
This blind spot is not an oversight — it is a structural limitation. Publication-based KOL identification will always skew toward academic medicine. Conference tracking will always favor the same established voices. To find community treaters, you need different data sources entirely: prescribing patterns, claims data, referral networks, local society involvement, regional trial participation. No traditional KOL tool was designed to integrate these signals. For a deeper look at building a comprehensive identification framework that includes community-level treaters, see our guide on identifying and prioritizing KOLs.
Problem 5: Insights Go In, Nothing Comes Out
This may be the most consequential problem in the stack, because it directly undermines one of the highest-value functions an MSL team performs. Field-based insights — the qualitative intelligence gathered through peer-to-peer interactions with KOLs — are frequently cited as one of Medical Affairs' most important contributions to organizational strategy. Every pharma company says they value MSL insights. Very few have the infrastructure to actually use them.
The capture is not the problem. MSLs dutifully log insights after interactions. The problem is what happens next, which is usually nothing. Insights sit in CRM text fields or Vault records, tagged with broad categories, rarely read by anyone outside the immediate team. Quarterly insight reviews summarize a handful of highlights. The vast majority of captured intelligence never reaches the people who could act on it.
The missing layer is synthesis. Individual insights are anecdotal. Connected insights are strategic. When a trend emerges across multiple MSL territories — a consistent concern about a treatment protocol, a shift in prescribing rationale, an emerging unmet need — that signal is enormously valuable. But detecting it requires connecting hundreds of individual data points across regions, time periods, and therapeutic areas. No manual process scales to this, and no tool in the traditional MSL stack was designed for it.
Understanding how insights fit into the end-to-end MSL workflow makes this gap even clearer — insights are supposed to flow upstream from field interactions to strategic decisions, but the infrastructure to enable that flow simply does not exist in most organizations.
What “Better” Actually Looks Like
Describing the problem clearly is the easier part. What is harder — and more useful — is articulating what a structurally sound MSL technology layer would actually look like. Not a wishlist. Not a feature comparison chart. An architecture that addresses the root causes rather than the symptoms.
A Unified Data Layer
The foundation has to be a single, continuously updated data layer that combines every signal relevant to MSL work: publications, clinical trials, open payments, NIH grants, conference abstracts, prescribing data, engagement history, and field insights. Not aggregated into a data warehouse after the fact — unified at the entity level, so that a single KOL profile reflects everything known about that person across every source.
This is harder than it sounds. Entity resolution in healthcare — determining that “Dr. John A. Smith” in a PubMed citation, “J. Smith, MD” on a clinical trial record, and NPI 1234567890 are the same person — is a genuinely difficult technical problem. But it is a solved one, and solving it at the data layer eliminates the integration tax that cascades through every downstream tool.
Continuous Intelligence, Not Periodic Snapshots
KOL intelligence should update as the underlying data changes — not on a quarterly refresh cycle. When a new publication appears in PubMed, the relevant KOL profiles should reflect it within days, not months. When a clinical trial advances to the next phase, the investigators involved should be re-scored automatically. When an MSL logs an insight that echoes a pattern emerging in another region, the connection should be surfaced immediately.
This requires treating KOL intelligence as a living system rather than a periodic report. The technology to do this exists — continuous data ingestion, real-time scoring algorithms, event-driven architecture. What has been missing is the will to build it into a platform purpose-built for Medical Affairs, rather than retrofitting it onto tools designed for other workflows.
AI That Surfaces Patterns Humans Would Miss
The promise of AI in Medical Affairs is not automation for its own sake. It is the ability to detect patterns across datasets that no human could process manually. An emerging KOL whose recent publications signal a shift toward your therapeutic area. A community treater network that is driving adoption of a new treatment protocol. A cluster of field insights that collectively point to an unmet need no one has explicitly articulated.
These patterns exist in the data today. They are invisible because the data is fragmented and the tools are not designed to look for them. The right AI layer does not replace MSL judgment — it extends MSL perception. It surfaces the signal. The MSL applies the context, the relationship knowledge, and the scientific expertise that make the signal actionable.
Workflows Designed for MSLs from Day One
An MSL's workday does not look like a sales rep's. Their planning horizon is longer. Their engagement model is conversational, not transactional. Their success metrics are relational, not volumetric. The tools they use should reflect this from the ground up — not as a configuration option within a commercial platform, but as a fundamental design principle.
This means engagement tracking that captures relationship trajectories, not just interaction counts. Planning tools that update dynamically based on new intelligence. Insight capture that is seamless enough to happen in the flow of work, not as a compliance exercise after the fact. And analytics that measure what matters to Medical Affairs: engagement quality, scientific impact, strategic coverage, and KOL sentiment over time.
Insights That Flow Upstream Automatically
The ultimate measure of an MSL technology stack is whether field insights reach strategic decision-makers in a form they can act on. This means automated synthesis: clustering related insights, detecting emerging themes, quantifying the strength and prevalence of signals, and delivering them in context — not as raw text fields, but as structured intelligence tied to specific therapeutic areas, products, and strategic questions.
When this works, Medical Affairs becomes what it has always aspired to be: a strategic intelligence function that informs clinical development, commercial strategy, and medical communications with proprietary, field-derived intelligence that no other function can provide.
The Category Shift
The conditions for this shift are converging now, not because any single technology breakthrough made it possible, but because several forces matured simultaneously.
AI has reached the threshold of practical utility for healthcare data. Large language models can now parse unstructured medical text — publication abstracts, clinical trial descriptions, field insights — with sufficient accuracy to be genuinely useful. Entity resolution algorithms can disambiguate healthcare professionals across fragmented data sources at scale. Natural language processing can synthesize hundreds of field insights into structured themes. Two years ago, these capabilities were experimental. Today, they are production-ready.
MSL teams are growing, and the role is expanding. Since 2020, the MSL function has expanded significantly in scope. MSLs are increasingly involved in launch strategy, real-world evidence generation, and patient advocacy — responsibilities that demand better tooling. A team of 10 MSLs could manage with spreadsheets and phone calls. A team of 80, operating across multiple therapeutic areas and geographies, cannot.
ROI scrutiny on Medical Affairs is intensifying. For years, Medical Affairs operated with less financial scrutiny than commercial or clinical functions. That era is ending. Pharma companies are asking what their Medical Affairs investment produces, and “we had a lot of good interactions” is no longer a sufficient answer. Better tooling is not a convenience — it is the infrastructure required to demonstrate measurable strategic impact.
The point-solution era is reaching its natural limits. The MSL stack has been built tool by tool, each solving one problem and creating two integration challenges. Organizations are recognizing that the next layer of value does not come from adding another point solution — it comes from an integrated platform that treats the MSL workflow as a unified system. Companies like Bionara are building this integrated layer from scratch, starting from the data model up rather than bolting features onto an inherited architecture.
The next generation of MSL platforms will not be tools. They will be workflow infrastructure — the operating layer that connects KOL intelligence, engagement management, insight synthesis, and strategic analytics into a single system that reflects how MSL work actually happens.
How to Evaluate MSL Technology
If you are evaluating MSL technology — whether replacing existing tools or building a stack for a new therapeutic area — the following framework will surface the structural differences that matter more than feature lists.
Does it cover the full workflow, or just one stage?
A tool that handles KOL identification but not engagement planning forces your team to maintain a separate planning system and manually transfer data between them. A tool that handles engagement tracking but not KOL intelligence means your MSLs are planning interactions without current data on who they are engaging. Every gap between tools is a place where data is lost, time is wasted, and insights fail to connect. Evaluate the full workflow — from initial KOL discovery through ongoing engagement to insight synthesis — and map where each tool starts and stops.
Is KOL data continuously updated, or periodic snapshots?
Ask specifically about data freshness. When a new publication is indexed in PubMed, how long before it appears in the platform? When a clinical trial updates its status on ClinicalTrials.gov, how quickly is that reflected in investigator profiles? If the answer involves quarterly refresh cycles or annual database updates, the intelligence will always be behind the market.
Can it find community-level treaters, not just academic KOLs?
Ask what data sources the platform uses beyond publications and conferences. Does it incorporate prescribing data? Claims data? Open payments? Referral network analysis? If the identification methodology is publication-centric, it will surface the same established names that every competitor is already engaging. The differentiated value is in finding the physicians who influence treatment decisions at scale but do not appear in traditional KOL databases.
Are insights actionable, or just archived?
Ask to see how insights are surfaced after they are captured. Can the platform identify emerging themes across multiple MSL territories? Does it connect field insights to external signals (new publications, competitor activity, treatment guideline changes)? Can a Medical Director see a synthesized view of field intelligence without reading hundreds of individual records? If insights are captured but not synthesized, the platform is a filing cabinet, not an intelligence system.
Was it built for Medical Affairs, or adapted from commercial?
This is the most revealing question. Look at the data model. Are interactions modeled as discrete events (sales paradigm) or as part of ongoing relationships (MSL paradigm)? Is success measured by activity volume or engagement quality? Are the default reports designed for a commercial manager or a Medical Affairs Director? The answer tells you whether the platform understands the MSL function or is approximating it.
What is the real integration burden on your team?
Every tool claims to integrate with everything. Ask for specifics. How many distinct logins do MSLs need? How much manual data transfer happens between systems? What breaks when a connected system updates its API? What is the ongoing maintenance cost of the integrations? The honest answers to these questions reveal the true cost of ownership — which is almost always higher than the license fee suggests.
For teams building or rebuilding their MSL technology stack, our case studies illustrate how organizations have navigated these evaluation decisions in practice.
Key Takeaways
- The MSL technology stack was accumulated, not designed. Each tool solves a narrow problem while creating integration challenges that collectively consume 30-40% of MSL productive time.
- CRMs built for sales do not fit MSL workflows. The interaction-centric data model of commercial CRMs cannot capture the relationship-centric reality of Medical Affairs engagement.
- Static KOL data produces static strategy. Quarterly database updates cannot keep pace with a research landscape that shifts weekly. Continuous intelligence is no longer a luxury — it is a requirement.
- Community treaters are the largest blind spot in MSL tooling. The 97% of physicians who treat the majority of patients are invisible to publication-based KOL identification tools.
- Insights are captured but never synthesized. The data that could make Medical Affairs a strategic intelligence function sits unused in CRM text fields and document repositories.
- The next generation of MSL platforms will be workflow infrastructure, not point solutions. The organizations that invest in integrated, MSL-native platforms now will have a structural advantage in KOL engagement, field intelligence, and strategic impact for years to come.
The MSL technology landscape is not lacking in tools. It is lacking in architecture. The vendors who built the current stack solved real problems — engagement tracking, KOL profiling, compliance documentation. But they solved them in isolation, and the result is a fragmented experience that makes MSLs less effective than they should be. The shift is not about replacing one tool with another. It is about replacing a collection of disconnected tools with a unified system that treats the MSL workflow as what it actually is: a continuous, intelligence-driven process that connects KOL discovery, engagement strategy, field interactions, and strategic insights into a single coherent loop. That system is now technically possible. The question is which organizations will build on it first.